Plasma RIPK3 And HMGB1 Predict Severe COVID-19 Progression In ICU Patients: A Single-Center Cohort Study
Abstract Background: Severe progression of coronavirus disease 2019 (COVID‑19) causes respiratory failure and critical illness. Recently, these pathologies have been associated with necroptosis, a receptor‑interacting serine/threonine‑protein kinase 3 (RIPK3) dependent regulated form of inflammatory cell death. Investigations of indicator necroptosis proteins like RIPK3, mixed lineage kinase domain‑like pseudokinase (MLKL), receptor‑interacting serine/threonine‑protein kinases 1 (RIPK1), and high‑mobility group box 1 (HMGB1) in clinical COVID‑19 manifestations are lacking.Methods: A prospective prolonged cohort study including 46 intensive care unit (ICU) patients classified with moderate and severe COVID‑19 was conducted with daily measured plasma levels of indicator necroptosis proteins like RIPK3, MLKL, RIPK1, and HMGB1 by enzyme‑linked immunosorbent assay (ELISA). On this basis, a multiple logistic (regression) classification for the prediction of severe COVID‑19 progression was performed. Results: We found significantly elevated RIPK3, MLKL, HMGB1, and RIPK1 levels in COVID‑19 patients admitted to the ICU compared to healthy controls throughout the ongoing disease, indicating necroptotic processes. Above all, with combined measurements of RIPK3 and HMGB1 plasma levels, we were able to time‑independently predict COVID‑19 severity with 84% accuracy, 90% sensitivity, and 76% specificity.Conclusion: We suggest that HMGB1 and RIPK3 are potential biomarkers to identify high‑risk COVID‑19 patients and developed a classifier for COVID‑19 severity.